San Antonio Breast Cancer Symposium | Conference

TNBC Subtype Responds Favorably to Neoadjuvant Bevacizumab

December 11th 2014

The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.

Dr. Francis on the Benefits of Ovarian Suppression for Younger Women

December 11th 2014

Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial

December 11th 2014

Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.

Dr. Weigert on Cancer Screening for Women With Dense Breasts

December 10th 2014

Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC

December 10th 2014

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

Pembrolizumab Elicits Antitumor Responses in TNBC

December 10th 2014

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

Early Data Find the PI3K Inhibitor Pictilisib Benefits a Subset of Patients With MBC

December 10th 2014

The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.

Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels

December 10th 2014

Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Dr. Shapiro on Preventative Drugs in Breast Cancer

January 27th 2014

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Dr. Piccart on a 4-Year Follow-Up of the NeoALTTO Trial

January 14th 2014

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

Dr. Neumayer Discusses the POWER PIINC Trial

December 18th 2013

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Dr. Turner Discusses the PALOMA-3 Trial

December 17th 2013

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Dr. Garner Discusses the myRisk Hereditary Cancer Test

December 16th 2013

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Postneoadjuvant Bisphosphonate Benefits in Breast Cancer Linked to Age, Menopausal Status

December 16th 2013

Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

Dr. Esserman Discusses the I-SPY 2 Trial

December 16th 2013

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Dr. Brenner on the Link Between Breast Cancer and Obesity

December 13th 2013

Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.

Dr. Julie Gralow Discusses the SWOG S0500 Trial

December 13th 2013

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.

Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC

December 13th 2013

The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.

Ramucirumab Does Not Prolong PFS in HER2-Negative Metastatic Breast Cancer

December 13th 2013

Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.

CTCs Prognostic But Not Helpful In Switching Therapy in MBC

December 13th 2013

Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.